Proposed changes to ABPI Code of practice could hurt smaller firms, warns EMIG - update
This article was originally published in Scrip
Executive Summary
Proposed changes to the ABPI (Association of the British Pharmaceutical Industry) code of practice, now out for consultation, could help improve transparency in the pharmaceutical industry. But plans to limit branded giveaways to healthcare professionals could disproportionately hurt smaller firms, making the code "unfit for purpose", warns the Ethical Medicines Industry Group, EMIG.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.